Learn about the world of investing from the world’s best speakers. Collision is back in Toronto in 2024, bringing together attendees from every sector.
- 40,000+ Attendees
Join tech's most innovative
From your living room
- Volunteer At Collision
Our volunteer program is a great
way to get involved with ...
- 40,000+ Attendees
Suchergebnisse
Suchergebnisse:
Novo Holdings is a holding and investment company that manages the assets of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations. It invests in life science companies and other assets with a long-term return perspective and a focus on health and sustainability.
- About
Novo Holdings is the controlling shareholder of Novo Nordisk...
- Investments
Novo Holdings is a world-leading life science investor. In...
- People
People - Novo Holdings · Home
- News & Reports
News & Reports - Novo Holdings · Home
- Career
Career - Novo Holdings · Home
- Novo Group
The Novo Group is a group of three independent companies...
- Novo Holdings · Leadership
The Novo Holdings Board of Directors is comprised of nine...
- Novo Holdings · Investments · esco
Date of investment. April 2021. Esco Lifesciences Group...
- About
Novo Holdings A/S ist ein dänischer Pharmahersteller; zu der Novo-Gruppe gehören die eigenständigen agierenden Tochterunternehmen Novo Nordisk, Novozymes und NNIT. Die Novo Holdings gehört der Novo Nordisk Foundation und ist Hauptanteilseigner der drei Pharmaunternehmen.
- Kasim Kutay (CEO)
- Aktieselskab
- 51 (Holding)
Novo Holdings A/S (formerly Novo A/S) is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S. Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation 's assets, which in 2023 was worth almost DKK 1,114 billion.
- 1999
- Life Sciences, Asset management
5. Feb. 2024 · Novo Holdings, die Holdinggesellschaft der Unternehmensstiftung Novo Nordisk Foundation, sichert sich mit dem Zukauf weltweit mehr als 50 Standorte von Catalent. An Novo Nordisk soll eine...
5. Feb. 2024 · Novo Nordisk announces a deal to buy three manufacturing sites from Novo Holdings, a subsidiary of Novo Nordisk Foundation, as part of a transaction with Catalent, a global CDMO. The acquisition will expand Novo Nordisk's filling capacity and flexibility for diabetes and obesity treatments.
